TURKU, FI / ACCESS Newswire / May 5, 2026 / Faron Pharmaceuticals Ltd. ("Faron") (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on creating innovative ...

Faron Pharmaceuticals, a clinical-stage biopharmaceutical company based in Finland, has announced that it has treated 255 patients with its experimental bexmarilimab (bex) treatment, which helps the ...

TURKU, FI / ACCESS Newswire / May 4, 2026 / The annual general meeting ("AGM") of Faron Pharmaceuticals Ltd (LSE:FARN)(First North:FARON) took place in Turku, Finland, today 4 May 2026. Thirty-nine ...

Faron Pharmaceuticals has pointed to the latest snapshot of early-stage data as proof that its tumor-associated macrophage candidate bexmarilimab is ready to enter phase 2 trials this year. The ...

TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based ...

TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel ...

Faron Pharmaceuticals has zeroed in on low levels of interferon-beta bioactivity to explain why its phase 3 traumakine trial failed comprehensively. The biotech is now testing product batches to ...

TURKU, FI / ACCESS Newswire / March 26, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi ...

In a year already marked by critical scientific milestones, Faron Pharmaceuticals is set to take center stage once again. The clinical-stage biopharmaceutical company has announced that detailed Phase ...

Strategic collaboration with a leading global CRO supports disciplined trial execution and operational efficiency, advancing Faron's mission to provide treatment for patients with HR-MDS TURKU, FI / ...